Corcept Therapeutics Incorporated reiterated revenue guidance for the year 2022. 2022 revenue guidance of $400 million to $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.62 USD | -0.62% | +2.84% | -11.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.88% | 2.98B | |
+37.74% | 723B | |
+34.71% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.21% | 244B | |
+9.96% | 208B | |
-4.13% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Reiterates Revenue Guidance for the Year 2022